PNPLA3 and metabolic dysfunction-associated steatohepatitis: Recently, Lindén et al. demonstrated the amelioration of NASH and hepatic fibrosis in human PNPLA3 I148M knock-in mice compared to wild-type mice, thus indicating an important role of hepatocyte PNPLA3 I148M as a potential target for intervention in liver fibrosis [141].